- Home
- LFST vs IBRX Comparison
LFST vs IBRX Comparison
Compare LFST & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFST
- IBRX
- Stock Information
- Founded
- LFST 2015
- IBRX 2014
- Country
- LFST United States
- IBRX United States
- Employees
- LFST N/A
- IBRX N/A
- Industry
- LFST Medical/Nursing Services
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LFST Health Care
- IBRX Health Care
- Exchange
- LFST Nasdaq
- IBRX Nasdaq
- Market Cap
- LFST 2.3B
- IBRX 2.4B
- IPO Year
- LFST 2021
- IBRX N/A
- Fundamental
- Price
- LFST $5.94
- IBRX $2.66
- Analyst Decision
- LFST Strong Buy
- IBRX Strong Buy
- Analyst Count
- LFST 5
- IBRX 5
- Target Price
- LFST $8.50
- IBRX $11.40
- AVG Volume (30 Days)
- LFST 2.0M
- IBRX 11.3M
- Earning Date
- LFST 05-07-2025
- IBRX 05-12-2025
- Dividend Yield
- LFST N/A
- IBRX N/A
- EPS Growth
- LFST N/A
- IBRX N/A
- EPS
- LFST N/A
- IBRX N/A
- Revenue
- LFST $1,283,503,000.00
- IBRX $31,222,000.00
- Revenue This Year
- LFST $15.35
- IBRX $579.01
- Revenue Next Year
- LFST $13.72
- IBRX $173.61
- P/E Ratio
- LFST N/A
- IBRX N/A
- Revenue Growth
- LFST 16.31
- IBRX 10238.41
- 52 Week Low
- LFST $4.64
- IBRX $1.83
- 52 Week High
- LFST $8.61
- IBRX $7.63
- Technical
- Relative Strength Index (RSI)
- LFST 46.63
- IBRX 53.05
- Support Level
- LFST $5.47
- IBRX $2.43
- Resistance Level
- LFST $6.18
- IBRX $2.79
- Average True Range (ATR)
- LFST 0.20
- IBRX 0.23
- MACD
- LFST 0.05
- IBRX 0.02
- Stochastic Oscillator
- LFST 66.20
- IBRX 53.80
About LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.